TABLE I -.
Ranking according to the surface under the cumulative ranking curve and mean rank for the efficacy outcomes
| Treatment | Surface under the cumulative ranking curve | Mean rank |
|---|---|---|
| Seizure response | ||
| Brivaracetam | 46.2 | 3.7 |
| Cenobamate | 99.0 | 1.1 |
| Eslicarbazepine acetate | 53.4 | 3.3 |
| Lacosamide | 60.8 | 3.0 |
| Perampanel | 40.7 | 4.0 |
| Placebo | 0.0 | 6.0 |
| Seizure freedom | ||
| Brivaracetam | 72.4 | 2.4 |
| Cenobamate | 88.8 | 1.6 |
| Eslicarbazepine acetate | 47.2 | 3.6 |
| Lacosamide | 37.8 | 4.1 |
| Perampanel | 53.0 | 3.4 |
| Placebo | 0.8 | 6.0 |
Higher values of surface under the cumulative ranking curve correspond to higher probabilities of better efficacy.